Produced by Streptomyces species, 1 natural Cyclophostin (CyC1 -Figure 1 ) is characterized by a unique seven-membered cyclic phosphate triester fused to a butyrolactone ring. This bicyclic core also contains a unique enol phosphate and chiral centers at both phosphorus and C-3a carbon atom. The structurally related natural Cyclipostins (e.g., Cyclipostin P CyC18 - Figure 1) , which varied in the nature of the lipophilic chain attached to the phosphate, were described as bacterial growth inhibitors of various mycobacteria. 2 Together, compelling evidence suggests the great potential for cyclic enolphosphate and phosphonate analogs of Cyclophostin (and the Cyclipostins) as anti-mycobacterial agents.
To explore this hypothesis, we have reported the synthesis of Cyclipostins and Cyclophostin analogs (namely the CyCs - Figure 1 ). [3] [4] [5] [6] We first demonstrated that this first series of 26 CyCs (Figure 1 ) was able to efficiently inhibit the growth of Mycobacterium tuberculosis H37Rv, in vitro as well as in infected macrophages, with very low toxicity towards the host cells. 7 These studies also strongly support the assumption that CyC compounds are multi-target inhibitors impairing various mycobacterial Ser-or Cys-containing enzymes involved in important physiological processes via the formation of a covalent bond between the enol-phosphorous atom and the catalytic residue. [4] [5] [7] [8] [9] The efficiency/selectivity of these CyCs was investigated further towards three slow-growing species (i.e., M. marinum, M. bovis BCG, and M. tuberculosis) and various mycobacterial clinical isolates and bacteria responsible for nosocomial infections, including Gram-negative and Gram-positive bacteria as well as rapidly-growing mycobacteria (RGM) belonging to the Mycobacterium chelonaeabscessus clade. 10 Remarkably, the inhibitory activity of these CyCs was exclusively restricted to mycobacteria. 10 Notably, the most potent inhibitor (CyC17) exhibited minimal inhibitory concentrations (MIC) values comparable to those of most classical antibiotics used to treat M. tuberculosis and M. abscessus infections. 7, 10 Collectively, these results emphasized the attractiveness of this new family of compounds as valid drug candidates to be exploited in future therapeutic developments against mycobacterial-associated infections, especially against M. abscessus the most drug-resistant mycobacterial species. 10 Over the last decade, non-tuberculous mycobacterial (NTM) infections have increased worldwide, leading to an emerging public health problem, particularly in industrialized countries, sometimes surpassing tuberculosis. 11 Among them, M. abscessus represents the most important rapidly growing mycobacteria (RGM). 12 M. abscessus is indeed responsible for a wide spectrum of clinical syndromes ranging from skin infections to severe pulmonary infections in humans with compromised natural defenses, such as patients with cystic fibrosis (CF). [13] [14] The M. abscessus complex, along with Mycobacterium avium complex, represents over 90% of all reported NTMpulmonary infection cases in CF patients. [15] [16] Reports also show that M. abscessus isolated from CF patients ranged from 16% and up to 68% of all isolated NTM. [17] [18] [19] In addition, the presence of M. abscessus infection prior to lung transplantation represents a risk factor for developing lung infection or a disseminated disease after transplantation. 14 M. abscessus displays rough (R) and smooth (S) colony morphotypes. [20] [21] The S morphotype is related to the abundance of the surface-associated glycopeptidolipids (GPL), which is associated with sliding motility and biofilm formation. 20 In contrast, a remarkable reduction in GPL amount in the cell wall of the R variant was correlated with cord formation. 22 In addition, S and R variants can be considered as two representatives of the same isolate, which may coexist and/or evolve differently in response to host immunity, resulting in different fates for the mycobacteria in its host. 20 Several studies have confirmed the correlation between colony morphology and virulence. The S variants are less virulent than R variants, 23 which are frequently associated with severe pulmonary infections [24] [25] and are able to persist for years especially in infected CF patients. 26 In the light of these findings, M. abscessus is known to transition from a smooth (S) morphotype with cell surface-associated GPL to a rough (R) morphotype lacking GPL. Accordingly, M. abscessus is notorious for being one of the most drug-resistant mycobacterial species, refractory to standard antimicrobials used for the treatment of Gram-positive and Gramnegative bacteria. 27 In addition, most antitubercular agents (i.e., rifampin, isoniazid, and ethambutol) are also ineffective against M. abscessus, referred to as an "antibiotic nightmare". 28 This intrinsic polyresistance to drugs results from multiple factors, 29 including the presence of a highly impermeable cell envelope preventing the penetration of drug, multiple-drug efflux pumps, [30] [31] inability to convert prodrugs into their active metabolites, 32 expression of numerous enzymes which can modify the drug-target or inactivate the drug itself, 27 and the acquisition of mutations in the antibiotic targets. Hence, the development of new therapeutic approaches and/or discovery of new chemical entities to fight this pathogen are needed.
Herein, we have synthesized 12 new analogs, i.e. CyC19 to CyC30, by varying the lipophilicity of the R 3 chain located on the 7-membered enolphosphorus ring in our phosphate and phosphonate analogs. This structural modification is also supported by the isolation of the anti-malarial Salinipostins, [33] [34] which are essentially Cyclipostins with variations in the enol alkyl substituent. 6 Their respective antibacterial activity was further assessed against a panel of pathogenic mycobacteria, including the M. abscessus R and S variants. Importantly, the MIC of all (26+12) CyCs determined against either extracellular or intracellular M. abscessus growth, revealed the efficacy of eight new candidates. The potential targets of CyC17 and CyC26, the two most potent inhibitors against extracellularly-growing bacteria, were identified via an activity-based protein profiling (ABPP) approach.
RESULTS AND DISCUSSION

Synthesis of new Cyclophostin phosphate and phosphonate analogs.
We incremented the already available library comprising 26 CyC compounds (i.e., CyC1-18 including the cis-() and trans-() isomers), 7, 10 by synthesizing 12 additional analogs (CyC19-30) from various 3-keto esters following previously described synthetic routes (Scheme 1). [3] [4] [5] [6] The general approach previously used for the synthesis of phosphonate analogs CyC4-10 was applied (Scheme 1A) to the synthesis of cyclic phosphonates with variation in the enol alkyl substituent (CyC19-22). The palladium-catalyzed substitution reaction of methyl or ethyl acetoacetate derivatives (2) 35 with the allylic carbonate (1) gave the vinyl phosphonates (3) as an E/Z mixture in good yields (35-63%) . The E and Z isomers could be separated by silica gel chromatography, but were generally taken into the next reaction as mixture. Quantitative hydrogenation of (3a-d) led to the saturated phosphonates (4a-d), which after selective demethylation and cyclization gave the racemic forms of monocyclic enolphosphonates (5a-d) corresponding to compounds CyC19 to CyC22 (17-62%, 2 steps).
To optimize the potent observed antibacterial activity of compound CyC17, 7, 10 the synthesis of various monocyclic phosphate analogs has also been completed. Following a literature procedure [36] [37] β-ketoesters (8a-d) were prepared by alkylation of t-butyl acetoacetate derivatives (7a-d) with iodide (6) 38 (Scheme 1B). The tert-butyl ester was chosen so as to minimize the risk of lactonization upon deprotection of the alcohol function. Reaction of compounds (8a-d) with dimethyl chlorophosphite followed by oxidation of crude material with I2 and methanol gave the enolphosphates (9a-d) in modest yield along with recovered starting material (21-49%, 49-81% BRSM). The 4-methoxybenzyl ether (PMB) protecting group was then removed with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) under standard conditions to afford alcohols (10a-d).
Demethylation and subsequent cyclization using 1-mesitylene-sulfonyl-3-nitrotriazole (MSNT) gave the monocyclic phosphate tert-butyl esters CyC27 to CyC30 (11a-d). Cleavage of the tert-butyl moiety with TFA in anhydrous conditions followed by TMSCHN2 treatment resulted in the formation of the corresponding racemic cyclic enolphosphate methyl esters CyC23 to CyC26 (12a-d) in good yields (79-100%). relative to the positive growth control (i.e., bacteria without antibiotics). Moreover, and as previously observed with CyC1 to CyC18, 10 this inhibitory activity was restricted to the four mycobacteria tested, while growth of E. coli and P. aeruginosa was not impacted (see Supplementary Material Table   S1 ). The MIC of these selected CyC21, CyC22, CyC25, CyC26 and CyC30 towards each mycobacterial strain were next determined using the resazurin microtiter assay (REMA) 7, 10 ( CyC22 exhibited the best activity (MIC50 5.6-8.7 μM) against M. tuberculosis mc 2 6230. These latter compounds represent two new potential candidates against this bacterium, therefore extending the first series of CyC growth inhibitors previously identified. 7, 10 Despite the fact that only CyC25 and CyC26 were active against M. abscessus on solid medium ( Table S2 ). CyC25 (MIC50 = 13.9 µM) and CyC26 (MIC50 = 6.9 µM) were confirmed as very good antimycobacterial molecules, in addition to CyC17 (MIC50 = 0.37 µM) and
CyC18 (MIC50 = 8.9 µM). 10 Of interest, these latter four best inhibitors of M. abscessus growth were all phosphate esters bearing a long lipophilic C10 / C16 alkyl chain either at the R 1 or R 3 position (Figure 1 and Scheme 1). M. abscessus surface-exposed GPL drives the antibacterial potency of CyC compounds. From these results, M. abscessus R appeared to be 6.1-to 34-times more sensitive than M. abscessus S to CyC25, CyC26 and CyC17 ( Table 1) . As previously mentioned, the major difference between these two variants resides in the loss of surface-associated glycopeptidolipids (GPL) in the R form. 20, 23, 39 It may be inferred that the GPL covering the surface of M. abscessus S acts as a protective shield towards the CyCs, although the natural Cyclipostin P CyC18β was not strongly affected by the GPL profile.
To confirm the possible relationship between CyC potency and GPL production, drug susceptibility was assessed using the GPL-deficient mmpL4b mutant generated in an S background of the type strain CIP104536 T , and its complemented counterpart. [40] [41] [42] The mmpL4b gene encodes for the MmpL4b membrane protein, which allows translocation of GPL across the plasma membrane. 40, 43 Mutations in this gene result in the loss of GPLs and acquisition of a R morphotype. 23, [40] [41] Both the wild-type M. abscessus S and the mmpL4b complemented strain responded similarly to CyC17, CyC25 and CyC26, with a more pronounced resistance level to these compounds as compared to the GPL-deficient mmpL4b mutant, which behaved like the wild-type R variant (Figure 2 and Table   2 ). Accordingly and as observed with M. abscessus S vs. R variant, the MIC50 of CyC25, CyC26 and
CyC17 reached on the mmpL4b complemented strain were 4.8-to 32-times higher than those determined on the mmpL4b deletion mutant ( Table 2 ). In contrast, there was a low influence of the GPL content in the activity of CyC18β, as judged by the obtained MIC50 values against different strains ( Table 2 ). a MIC50 corresponding to the concentration leading to 50% growth inhibition as determined by the REMA assay, are expressed as mean values of two independent assays performed in triplicate (CV% <5%). smegmatis_lipg mutant strain in which GPLs were overexpressed due to disruption of lipG, resulting in a change vs. WT in MIC50 value of ×15.7 fold. 44 Both results are also in agreement with a study 45 reporting that M. avium GPL-positive serovar was less sensitive to ethambutol than GPL-negative one, presumably because hydrophobic GPL may alter cell-wall fluidity/permeability and correlate with antibiotic tolerance. [45] [46] Together, these findings underline the importance of the surfaceexposed GPL in the CyC-dependent inhibition of M. abscessus growth. Remarkably, CyC18β, which differs from CyC17 by the presence of a butyrolactone ring fused to the seven-membered cyclic phosphate triester (Figure 1) , failed to show a high GPL-dependent activity profile. Accordingly, the presence of the lactone may be responsible for this behavior, different from the other monocyclic CyC analogs, towards M. abscessus variants.
Activity-based protein profiling (ABPP) approach for targets identification. In light of our previous study demonstrating the strong affinity of the CyCs for (Ser/Cys)-enzymes bearing a catalytic serine or cysteine residue, 4-9, 37, 47-48 we presumed that these inhibitors would also target/impair the activity of enzymes participating in a wide range of physiological processes of the M. abscessus life cycle, resulting in bacterial growth inhibition, as previously shown in M. tuberculosis. 7 Hence, to gain access to their putative targets, activity-based protein profiling (ABPP) 7, 49-50 was employed to capture and identify candidate target enzyme(s) impacted by CyC17 and CyC26, the two best hits acting against extracellular M. abscessus.
In the first approach, a crude lysate of M. abscessus R was incubated with either a CyC inhibitor (or DMSO as a control) and subjected to a competitive probe labeling/enrichment assay with a Desthiobiotin-FP probe (see Supplementary Material Figure S1A ). 7 The enriched mixtures were then digested with trypsin and the resulting peptides analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS), followed by subsequent label free quantification analysis. The proteins that were also found in the control experiment (i.e., DMSO alone for unspecific binding to streptavidin-magnetic beads) were discarded. At first, proteins identified with a permutation false discovery rate (pFDR) up to 10% were selected, leading to a panel of 806 distinct protein candidates in the case of CyC17, which was narrowed down to 30 when applying a pFDR of 1%, as compared to only 4 with CyC26 (14 at a pFDR of 10%) (see Supplementary Material Tables S3-S8) .
Given the fact that orthologs typically perform equivalent functions in the respective organisms, 51 Interestingly the histidinol-phosphate aminotransferase (i.e., MAB_2669c or HisC1), possibly involved in the histidine pathway and annotated as an essential enzyme in M. tuberculosis, [52] [53] was also uncovered with CyC26. All target-proteins of CyC26 were also identified with CyC17, thus confirming this latter as a broader multi-target inhibitor. Given the putative mechanism of action of HisC1 (MAB_2669c) together with the recent resolution of the 3D structure of its M. tuberculosis ortholog Rv1600 in complex with its natural substrate, i.e. pyridoxal-5'-phosphate (PDB id: 4R8D), 54 one can hypothesize that the two phosphate analogs CyC17 and CyC26 may bind to the active site, thus acting as substrate-like adducts.
In the second approach, the penetration/diffusion of CyC17 inhibitor through the mycobacterial cell wall was taken into account in order to reduce the list of potential targets. Thus, a similar experiment was performed on living bacterial cells. 55 M. abscessus R cells were grown to log phase and incubated with CyC17 (or DMSO as a control). After cell lysis, part of the lysate was processed as described above with Desthiobiotin-FP probe and streptavidin magnetic beads (see Table S6 ). It is noteworthy that among these 39 potential hits, 24 were previously detected in the CyC17-treated total lysate (see Supplementary Material Tables S3-4 Table S6 ).
Interestingly, 9 out of the 39 identified proteins are annotated as essential enzymes in M. tuberculosis genome ( Table 3) . 52 Of particular interest, the Ag85A/B/C proteins from M. tuberculosis have been recently validated as real targets of CyC17. 7, 9 Herein, we confirm that the recombinant M. abscessus Ag85C protein, which shares nearly 60% amino acid sequence identity with its M. tuberculosis ortholog and possesses the same conserved catalytic triad (i.e., Ser 124 -Glu 228 -His 260 ), is also inactivated by CyC17.
Ag85CMabs ( Oxadiazolone-core derivatives. 55 From these findings, all 38 CyC analogs were further tested for their antibacterial activity against M. abscessus growth inside infected macrophages.
The cytotoxicity of the 12 new compounds was first assessed using murine Raw264.7 macrophages. 61 Except CyC26 (CC50 = 50 µM), all other inhibitors CyC19-25;27-30 showed very low toxicity towards the cells with CC50 > 100 μM, similarly to AMK (CC50 ≥150 μM). 62 Taking into account our previous toxicity results obtained with CyC1-18, 7 phosphate (i.e., CyC17) chemical groups have been reported for M. tuberculosis. 7 In addition, the fact that only CyC7(α,β) and CyC8(α,β) showed a clear preference against intracellularly-replicating mycobacteria may imply that the intracellular mode of action of these CyCs differs from that of CyCs acting exclusively on extracellularly-replicating bacilli. Another hypothesis is that accessibility and/or vulnerability of their corresponding target(s) may be more apparent and crucial during the intracellular lifestyle of M. abscessus. Moreover, a specific stringent response of the macrophage, such as possible host cell metabolism, stimulated by the action of these latter compounds and leading to bacterial clearance cannot, however, be excluded.
To confirm this screen, M. abscessus S infected macrophages were subjected to a dose-response assay using the latter selected CyC7(α,β) and CyC8(α,β) analogs or IMP (Figure 3) , taken as reference intracellular drug, in order to determine their respective intracellular MIC50Raw values ( Table 4 ). Both
CyC7α and CyC7β displayed a moderate activity against intracellular M. abscessus S (Figure 3A) with a calculated MIC50Raw of 29.3 µM and 65.3 µM, respectively, similar to that of IMP (MIC50Raw = 28.3 µM) used as reference ( Table 4) . By contrast a 24 h-treatment with either CyC8α or CyC8β led to a 68.4 ±6.4% (30-60 µM) and 73.5 ±1.9% (60 µM) reduction in mycobacteria, respectively; which was comparable to that elicited by IMP, i.e., 74.0 ±4.4% reduction following treatment with 60 µM (Figure 3C) . Regarding CyC8β, a plateau value corresponding to 64.7 ±3.8% bacterial killing was reached when the infected cells were treated with the compound at a 5-30 µM concentration range.
Remarkably, MIC50Raw values of CyC8α (7.9 µM) as well as CyC8β (2.0 µM) towards intramacrophagic bacilli were 3.6-and 14-fold lower than that of IMP (28.3 µM) ( Table 4 ). These improving the current treatments against these mycobacterial infections.
EXPERIMENTAL SECTION
Chemistry -synthesis of compounds CyC19 to CyC30
The synthesis of natural Cyclophostin CyC1, 4 its phosphonate analogs CyC2 and CyC2, 3 the monocyclic enolphosphonates CyC3-4 47 and the trans-() and cis-() diastereoisomers CyC5-10; 5 as well as the trans-() and cis-() Cyclipostin P CyC18 4 and the corresponding monocyclic phosphonate CyC11-13, 5, 7 difluorophosphonate CyC14-15 and phosphate CyC16-17 6, 37 analogs have already been reported. The 12 new analogs (CyC19-30) where synthesized in racemic form from various 3-keto esters following already described synthetic routes (See Supplementary Material for detailed procedures and the full chemical characterization of each new compounds), [3] [4] [5] [6] and have purity of ≥ 95% as determined by HPLC analysis as reported previously. 5 The HPLC data were supported by careful analysis of the 1 H, 13 C and particularly the 31 P NMR spectra (see 40 and its complemented counterpart (M. abscessus S_mmpL4b::C), which stably expresses MmpL4b under the control of the hsp60 promoter, were also used as previously reported in 20 .
Antibiotics. Amikacin was purchased from Euromedex (Souffelweyersheim, France), and imipenem was provided by Mylan (Saint-Priest, France). Stock solution in water were freshly prepared for each experiment and filtered through a sterilized 0.22-µm-pore-size polycarbonate syringe filter (Millipore, Saint-Quentin-en-Yvelines, France).
Drug susceptibility testing on solid medium.
This was performed in 24-well suspension culture plates (Greiner bio-one) as described previously. 66 aeruginosa. Each well was spotted with 10 µL of a bacterial culture at 5 × 10 5 cells/mL. Colonies were counted after 1 day to 2 weeks of incubation at 37 °C, depending on the strain tested, to check bacterial viability. The CyC compounds leading to a minimum of 50% growth inhibition from CFU count were selected for subsequent MIC determination using the REMA assay.
Resazurin microtiter assay (REMA) for MIC determination. The concentrations of compound
leading to bacterial growth inhibition were first determined using the resazurin microtiter assay (REMA). 7, 10, 55 Briefly, log-phase bacteria were diluted to a cell density of 5 × 10 6 cells/mL and 100 µL of this inoculum was grown in a 96-well plate in the presence of serial dilutions of compounds.
After 7-14 days incubation, 20 µL of a 0.025% (w/v) resazurin solution was added to each well (200 µL) and incubation was continued until the appearance of a color change (from blue to pink) in the control well (bacteria without antibiotics). Fluorescence of the resazurin metabolite resorufin (excitation, 530 nm; emission, 590 nm) was then measured, 7, 10, 55 and the concentration leading to 50% growth inhibition was defined as the MIC50. See Supplementary Material for detailed protocol. -CyC30 analogs (resazurin assay) 
Determination of cytotoxic activity for new CyC19
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